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Abstract
Uveal melanoma (UM) is the most prevalent intraocu-
lar malignant tumor in the Western world. The prog-
nosis of survival in the presence of metastatic disease
is 2-7 months, depending on the treatment applied.
This article presents a case of metastatic UM with
successful complex treatment of liver metastases. 
a  49-year  old  female,  underwent  removal  of  the
right eyeball in 1996 due to a histologically confirmed
uveal melanoma. after 11 years, CT revealed a mass in
the  left  kidney  and  multiple  metastases  in  the  liver. 
after left nephrectomy, 6 chemotherapy courses with
dacarbazine  were  performed.  The  increasing  liver
metastases  were  observed.  additional  4  intraarterial
(i/a)  chemotherapy  courses  were  administered  using
cisplatin,  doxorubicin,  fluorouracil,  and  interferon
alfa. after few courses increase in CTC Grade 4 liver
transaminases  was  seen.  a  partial  response  was  ob-
served, and in december 2008 the patient underwent
surgery removing all liver metastases by 7 wedge or
atypical  resections.  all  margins  were  tumor-free.  21
months after liver resections and 14 years since dia  -
gnosis, the patient is alive without evidence of disease.
successful treatment of metastatic uveal melanoma
was due to a timely application of a combination of
several treatment methods and good prognostic fac-
tors of the patient.
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InTRodUCTIon
Uveal melanoma (UM) is the most prevalent intraocu-
lar malignant tumor in the Western world. Most fre-
quently it develops in the choroid (80%) and the cil-
iary body (15%). The incidence of uveal melanoma in
the Western countries is 7 new cases per 1 million of
population annually [1]. five, ten and fifteen year sur-
vival is 65%, 52%, and 46% respectively. [2-5]. CoMs
(Collaborative ocular Melanoma study Group) indi-
cates that the incidence of metastases within 5 years is
25%, and patient mortality within 2 years in the pres-
ence of a metastatic disease is 92% [6,7]. Most fre-
quently  (about  60-80%  of  cases),  uveal  melanoma
metastasizes  into  the  liver  due  to  the  biological-
anatomical peculiarities (hematogenous dissemination,
subsequent homing of cancer cells or their preferen-
tial survival in the liver and other factors) [2-4]. other
common sites of metastasis are lungs and bones [6].
The  etiology  of  uveal  melanoma  is  not  entirely
clear.  The  disease  is  most  commonly  diagnosed  in
people with light eyes that are under prolonged expo-
sure to Uv-radiation. other possible etiological factors
are fair skin and oculodermal melanocytosis [1, 8, 9].
nowadays,  some  UM-related  genetic  changes  have
been identified, most frequently as chromosomal aber-
rations on chromosomes 1, 3, and 8. Monosomy 3,
gain of 8q, combination of loss of 1p36, and mono-
somy 3 are identified as factors that have a detrimental
effect on survival [1].
Unfortunately,  efforts  to  reduce  mortality  from
metastatic UM have not been very successful during
the last decades. The prognosis of survival in the pres-
ence of metastatic disease is 2-7 months, depending
on the treatment methods [1]. 1-year overall survival
(os) is 13-29% [10, 11]. The most common negative
prognostic factors are age (over 60 years), male sex,
short interval between primary diagnosis and manifes-
tation of first metastases, and multiple liver metastases
[10,12-14]. Metastatic UM requires complex therapy.
Most  frequently  treatment  includes  systemic  chemo  -
therapy  (dacarbazine,  fotemustine,  immunotherapy,
etc.) [6]. detection of isolated liver metastases compli-
cates  the  treatment  and  requires  surgery,  chemoem-
bolization  or  i/a  chemotherapy  to  ensure  maximum
destruction of neoplastic lesions. 
according  to  the  data  of  the  lithuanian  Canter
Registry  (Institute  of  oncology,  vilnius  University),
269 new cases of skin melanoma were registered in
2009, while the number of cases of UM is unknown.
In this article we would like to present a case of
metastatic UM with successful complex treatment of
liver metastases.
CasE REPoRT
a 49-year old female patient, underwent removal of
the right eyeball (enucleation bulbi) in 1996 for a his-
tologically confirmed uveal (choroid) melanoma. no
additional  treatment  was  applied.  Eleven  years  later
(11/2007),  computer  tomography  (CT)  revealed  a
mass in the left kidney and multiple metastases in liver,
involving both liver lobes. after initial interdisciplinary
consensus, a left nephrectomy was performed (reach-
ing  an  R0  situation),  while  systemic  chemotherapy
should  treat  the  liver  metastases.  Initial  surgery  was
notadministered due to size and multiple spread of the
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Fig. 1. Contrast-enhanced CT image of the liver shows multi-
ple unresectable liver metastases.
Fig. 2. Contrast-enhanced CT image of the liver shows par-
tial response after four courses of iintraarterial chemotherapy.
Fig. 3. (a) Melanoma metastasis in liver tissue: epithelioid and
spindled cell type melanoma cells on the left and across the
fibrous septa on the right – normal liver cell plates. HE x
100. (b) Melanoma metastasis in liver tissue: epithelioid and
spindled cell type melanoma cells on the left and across the
fibrous septa liver cell plates - one could see a bile duct in the
middle of the slide (black arrow). HE x 200. (c) Melanoma
cells with nuclear grooves and pigmentation, melanophages
(black arrows). HE x 400.
Fig. 4. (a) Melanoma cells are positive for HMb45 and s100
immunohistochemistry stains: membranous and cytoplasmic
for HMb45 and (b) nucleus and cytoplasmic for s100 (black
arrow). HE x 200.
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metastastic  disease  of  the  uveal  melanoma.  after-
wards,  6  cycles  of  dacarbazine  were  administered
(1000 mg/m2 1 day infusion every 3 weeks). an in-
crease of liver metastases (in size and in number) was
seen under this treatment.
body CT performed in June 2008 showed multiple
(about 10) metastatic lesions in both lobes, 11-26x38
mm in size; no other metastases were detected (fig. 1).
during June-october 2008, the patient underwent 4
courses  of  intraarterial  (i/a)  chemotherapy  (scheme:
cisplatin 100 mg/m2 day 1; doxorubicin 40 mg/m2 day
1; fluorouracyl - 500 mg/m2 days 1-3; interferon alfa -
4 MU/m2 days 1-3 with a 40-50 days interval). after
first and fourth course, an increase of liver transami-
nases was observed (according to CTC criteria - Grade
4), and thus chemotherapy on the third day was dis-
continued. after fourth course of i/a chemotherapy,
thrombocytopenia (CTC Grade 4) was observed, re-
quiring  afereted  thrombocyte  transfusion  (1  dose).
other side effects (CTC Grade 1-2) included nausea,
vomiting, and fever, but required no additional treat-
ment.
In november 2008, abdominal CT revealed partial
response  in  the  liver  (fig.2)  metastasis  according  to
RECIsT criteria. Therefore, interdisciplinary consen-
sus suggested surgical exploration and metastasecto-
my.
In december 2008 the patient underwent liver re-
section with the removal of all 7 lesions from liver. all
resections were performed as wedge or atypical resec-
tions, operative blood loss was 500 ml. Histology con-
firmed 5 from 7 nodules as metastases of initial uveal
melanoma (figs. 3-4), all resected with clear margins (2
from 7 near the resection border). The post-operative
period was uneventful, the patient could be discharged
on post-operative day 8. follow-up CT scans in sep-
tember 2009 and september 2010 revealed physiologi-
cal postoperative changes in the liver without detec-
tion of further metastases (fig. 5). at present, at 21
month after the removal of liver metastases, the pa-
tient is free of signs of recurrence. The patient’s con-
dition is excellent without complaints; liver function
and its markers are within the physiological range.
dIsCUssIon
We  presented  a  patient  with  complex  treatment  for
metastatic uveal melanoma. following the diagnosis of
metastasis  in  the  kidney,  a  nephrectomy  was  per-
formed, while liver resections of the metastases were
not recommended, though initially discussed. The pa-
tient underwent systemic chemotherapy, but it proved
to  be  ineffective.  subsequent  i/a  chemotherapy
(chemo  therapeutic agents with interferon) yielded par-
tial response, and the patient was interdisciplinary dis-
cussed as a candidate for definite surgery and success-
fully operated.
The choice of our treatment tactics was determined
by isolated liver metastases and good functional status
of the patient. The patient’s prognostic factors played
a significant role in the choice of treatment tactics and
the  prognosis.  The  patient’s  prognostic  factors  were
good: age below 60 years (35 years at the time of diag-
nosis), female sex, long period until the presence of
first metastases (11 years), and isolated metastases in
the liver. It is noteworthy that the patient also had neg-
ative prognostic factors – multiple liver metastases –
which resulted initially in the decision of not to per-
form the liver metastasectomy right away. It is note-
worthy though, that changes in the clinical results, sta-
ble disease as well as progressive disease and regres-
sion, in metastatic patients should always be again pre-
sented and discussed interdisciplinarily, since further
therapeutic options may always be discussed in an in-
dividual setting.
scientific  publications  most  frequently  define  the
following  negative  prognostic  factors  for  uveal
melanoma: ciliary body involvement detected on histo-
logical examination, and up to 10 liver metastases [12,
15]. other authors revealed that up to 4-5 liver metas-
tases without signs of micrometastases, and radically
performed resection of the liver metastases may result
in a better prognosis for metastatic disease [3, 6]. a
french  study  investigated  3873  patients  with  uveal
melanoma,  in  whom  798  patients  developed  liver
metastases [3]. furthermore, it was noted that time to
diagnosis of liver metastases (less than 24 months af-
ter primary diagnosis), non-radical resection of liver
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Fig. 5. (a) Contrast-enhanced CT image of the liver 9 and (b) 21 month after resection of the liver metastases shows only post-
surgical lesions.
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and confirmed milliary metastases all are negatively as-
sociated  with  overall  survival  [3].  Therefore,  a  close
follow-up  in  all  uveal  melanoma  patients  is  recom-
mended in order to detect possible metastases at the
earliest possible time. This enables a possible surgical
resection as well as possible systemic treatment aiming
at complete regression. The same study recommends
prevention in patients with diagnosed extensive uveal
melanoma. This is liver MRI, which is especially rec-
ommended in patients who after eyeball enucleation
are diagnosed with monosomy 3 (fIsH – fluorescent
in situ hybridization) [3, 16, 17]. We do not do genetic
test for uveal melanoma patients in lithuania routine-
ly.
When analyzing therapeutic techniques selected in
our patient, it is important to note the importance of
the removal of liver metastasis. The benefit of the re-
section of liver metastases has been confirmed by a
number of clinical studies. The following factors de-
termine the applicability of liver metastasis resection:
the patient’s good functional condition, absence of the
signs of disease dissemination, and anatomical size of
the tumor - 30-40% of liver parenchyma [12]. l. Kod-
jikian et al. analyzed 602 patients and indicated that
the most effective treatment techniques were radical
resection  of  liver  metastases  and  intraarterial
chemotherapy (with fotemustine or cisplatin), partial
resection  of  the  metastases  with  intraarterial
chemotherapy is less effective, but the poorest results
were  obtained  when  administering  best  supportive
care  [12].  The  experience  of  the  Institut  Curie
(france) confirms these results: in cases of R0 liver
metastasis  resection,  median  survival  (Ms)  was  27
months, compared to the overall post-operative Ms of
14  months  [3].  according  to  other  authors,  median
overall survival was 25 months in R0 liver metastasis
resection, 16 months – in R2 resection, and 11 months
– in systemic chemotherapy or best supportive care
[15]. In our case, the patient underwent the removal of
all  liver  metastases  visible  on  CT.  at  present,  at  21
months after the removal of liver metastases, the pa-
tient is free of signs of recurrence. The relevant point
in the analysis of the treatment options of UM liver
metastases is that surgery is important in case of sec-
ondary liver metastases as well. In such cases one can
also combine liver resection, chemoembolization, iso-
lated liver perfusion, etc. [10]. There have also been
vaccines tested following the resection of primary liv-
er metastases to delay secondary metastases [10, 18].
due  to  anatomical  peculiarities,  when  metastases
are located only in liver, and when immediate R0 liver
surgery  is  impossible,  i/a  chemotherapy,  chemoem-
bolization, or a combination of both can be applied.
due to size and multiple metastases in various liver
segments as well as in the kidney, initial surgery was
not chosen initially, but it was possible later. for this
reason, nephrectomy and neoadjuvant chemotherapy
were scheduled, followed by i/a chemotherapy (a com-
bination of platinum-based chemotherapy agents and
interferon)  [19].  The  patient  did  not  tolerate  i/a
chemotherapy very well, as shown by severe increase
in  liver  transaminases  and  severe  thrombocytopenia.
literature provides extensive descriptions of direct in-
trahepatic administration of chemotherapeutic agents
as adjuvant therapy to surgery. frequently the treat-
ment is initiated with surgical removal of metastases
[12, 15], while in our patient the surgical approach was
performed  after  i/a  chemotherapy  reducing  the
metastatic lesions (in size and number) and reevalua-
tion of the patient.
Chemoembolization or i/a chemotherapy are effec-
tive techniques for the treatment of liver metastases
since  usually  liver  metastases  are  hypervascular.  The
reported response rate to chemoembolization is 36%,
though  no  survival  benefit  compared  to  systemic
chemotherapy is reported [15, 20]. agents most fre-
quently  used  in  chemoembolization  and  i/a
chemotherapy are dacarbazine, cisplatin, fotemustine,
or their combinations [12, 15, 21, 22]. In our case, the
patient underwent 6 courses of systemic chemothera-
py with dacarbazine alone and therefore we selected a
combination of several platinum-based agents for i/a
chemotherapy.
The patient survived 14 years after initial diagnosis
and 21 months since removal of liver metastases. lit-
erature  indicates  that  median  overall  survival  in
metastatic uveal melanoma is 14-15 months when ap-
plying a combination of surgery with or without i/a
chemotherapy, and 11 months if surgery is contraindi-
cated and chemotherapy alone is applied [3, 15]. Medi-
an  survival  in  metastatic  uveal  melanoma  patients
treated by applying HaI (hepatic arterial infusion) of
cisplatin, vinblastine, and dacarbazine was 16 months
[21].  When  patients  underwent  transcatheter
chemoembolization (TaCE) of liver metastases with
cisplatin,  median  time  to  progression  is  8.5  months
[22];  when  applying  TaCE  with  fotemustine  or  cis-
platin, median os is 6 months. Currently, administra-
tion  of  i/a  fortemustine  as  an  adjuvant  therapy  in
high-risk UM patients is being analyzed [23]. There is
an ongoing EoRTC (18021) clinical trial comparing
the efficiency of i/a fotemustine vs systemic fotemus-
tine [3]. further studies are being conducted on the ef-
ficacy of the combinations of older chemotherapeutic
agents (dacarbazine) with temozolomide, gemcitabine
and thalidomide [2, 24-26].
In our patient, successful results of metastatic uveal
melanoma management were due to a timely applica-
tion of a combination of several treatment methods
and good prognostic factors of the patient. Though
initial evaluation ruled out surgical removal of the liver
metastases, reevaluation after several chemotherapeuti-
cal strategies lead to the surgical approach of resec-
tion. Therefore, reevaluation of patients with malig-
nancies,  even  with  systemic  disease,  should  be  per-
formed in order to gain the best possible survival out-
come for the individual patient.
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